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Abstract
Mild traumatic brain injury (mTBI) results in an estimated 75–90% of the 1.7 million TBI-related emergency room visits
each year. Post-concussion symptoms, which can include impaired memory problems, may persist for prolonged periods
of time in a fraction of these cases. The purpose of this study was to determine if an erythropoietin-mimetic peptide,
pyroglutamate helix B surface peptide (pHBSP), would improve neurological outcomes following mTBI. Sixty-four rats
were randomly assigned to pHBSP or control (inactive peptide) 30 lg/kg IP every 12 h for 3 days, starting at either 1 hour
(early treatment) or 24 h (delayed treatment), after mTBI (cortical impact injury 3 m/sec, 2.5 mm deformation). Treatment
with pHBSP resulted in significantly improved performance on the Morris water maze task. Rats that received pHBSP
required 22.3 – 1.3 sec to find the platform, compared to 26.3 – 1.3 sec in control rats ( p = 0.022). The rats that received
pHBSP also traveled a significantly shorter distance to get to the platform, 5.0 – 0.3 meters, compared to 6.1 – 0.3 meters
in control rats ( p = 0.019). Motor tasks were only transiently impaired in this mTBI model, and no treatment effect on
motor performance was observed with pHBSP. Despite the minimal tissue injury with this mTBI model, there was
significant activation of inflammatory cells identified by labeling with CD68, which was reduced in the pHBSP-treated
animals. The results suggest that pHBSP may improve cognitive function following mTBI.
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Introduction
Mild traumatic brain injury (mTBI) is a syndrome ofphysical, cognitive, emotional, and sleep-related symptoms
induced by a blow or jolt to the head.1 The clinical spectrum of
mTBI ranges from brief confusion with rapid recovery to loss of
consciousness for up to 30 min with prolonged disabling symptoms.
An estimated 75–90% of the 1.7 million TBI-related emergency
room visits each year are a result of mTBI.
Treatment of mTBI is primarily symptomatic. Several neuro-
protective agents have been investigated in the laboratory in mTBI
models, including tumor necrosis factor-a antagonists such as 3,6¢-
dithiothalidomide,2 sulfonylurea inhibitors such as glibenclamide,3
the PKC activator bryostatin 1,4 insulin-like growth factor,5 aden-
osine A1 receptor activation to inhibit microglia proliferation,6
glutamate antagonists like N-methyl-D-aspartate,7 free radical
scavengers such as vitamin E,8 exercise,9 Nogo-A inhibitory pep-
tide (NEP1-40),10 the nicotinic acetylcholine-receptor activator
donepezil,11 dehydroepiandrosterone sulfate,12 and mexiletine,13
but none so far has been successful in clinical studies. Most of these
agents target a specific pathophysiological injury mechanism. Gi-
ven the complex cascade of injury mechanisms induced by TBI, a
drug that has multiple neuroprotective activities might be more
advantageous.
One such agent is erythropoietin (EPO). It has neuroprotective
activities that include suppression of cellular inflammatory condi-
tions, inhibiting apoptosis, and improving cerebrovascular func-
tion, and it may enhance recovery by stimulating neurogenesis and
angiogenesis.14–21 However, the erythropoietic activities of EPO
are problematic in some clinical settings. Stimulating erythropoi-
esis may be an advantage in severe TBI, for which anemia is a
common complication. However, in mTBI, for which the hemat-
ocrit is usually normal, an increase in hematocrit is more likely to
predispose to thrombotic complications, some of which can be
serious and life-threatening.
Using derivatives of EPO, Leist and associates demonstrated
that the erythropoietic and cytoprotective effects of EPO can be
separated.22 A novel cell surface receptor, comprised of the
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classical EPO receptor (EPOR) disulfide, linked to the beta com-
mon receptor CD131, may mediate the non-hematopoietic effects
of EPO.23 An 11-amino acid synthetic peptide was subsequently
developed to mimic the 3D structure of EPO. This peptide re-
tains EPO’s neuroprotective activities, but not the erythropoietic
actions that are responsible for the thrombogenic adverse effects of
EPO.24 The peptide, called pyroglutamate helix B surface peptide
(pHBSP), is a linear peptide containing the amino acids from the
aqueous face of helix B (amino acids 58–85) of erythropoietin
(QEQLERALNSS). Modification of the N-terminal Q to pyr-
oglutamate (U) for stabilization results in a peptide (UEQLER
ALKSS) that can be stored for 2 years at 4C, or up to 12 months at
25C. Therefore pHBSP does not require refrigeration and may
have lower risk of adverse effects, which are important advantages
over EPO as a therapeutic agent in the treatment of mTBI.
In a model of mTBI followed by hemorrhagic shock, pHBSP had
neuroprotective activities equivalent to EPO.25 The purpose of this
study was to examine the neuroprotective effects of pHBSP in a
model of uncomplicated mTBI.
Methods
Sixty-four Long Evans rats weighing 300–400 grams were used
for this study. This protocol was approved by the institutional an-
imal protocol review committee at Baylor College of Medicine,
using guidelines for the humane care and use of animals that were
developed for the National Institutes of Health.
Treatment groups
Rats were randomly assigned to receive either pHBSP or control
treatment starting at 1 h (early treatment), or 24 h (delayed treat-
ment) after injury. Sixteen animals were assigned to each of the
four groups. The control group received an inactive peptide con-
sisting of the same amino acid components as pHBSP, but in a
scrambled sequence (ULSEARNQSEL). In a previous study this
control was similar to a saline control.25 The dose of both the
pHBSP and the control was 30 lg/kg IP starting at the assigned
time, and then every 12 h for 3 days. The investigators conducting
the injury experiment and the outcome measures were blinded to
the treatment assignment.
Anesthesia
General anesthesia was induced using 5% isoflurane in 100%
oxygen. The rats were placed in a vented anesthesia gas chamber
for approximately 3–5 min. Immediately after anesthesia induction,
the rats were intubated using a 14-gauge catheter. The rats were
then mechanically ventilated with 2% isoflurane in 100% oxygen,
and the ventilator was adjusted to maintain arterial partial carbon
dioxide pressure between 35 and 40 mm Hg, and partial oxygen
pressure >100 mm Hg.
Craniectomy and controlled cortical impact
The rat’s head was fixed in a stereotaxic frame for the injury. The
surgical procedure was performed using aseptic technique. The
rat’s scalp was shaved and then cleaned using an iodine-based
antiseptic solution. Placement of sterile linens over the rat’s head
was done to minimize the risk of contamination. A median skin
incision was performed and the scalp (including the periosteum)
and the temporalis muscle were reflected. To expose the brain for
the impact injury, a 10-mm-diameter craniectomy was made using
a dental drill over the right parietal cortex between the bregma and
the lambda. Care was taken to not injure the dura. A small amount
of saline solution was directed at the site of drilling to prevent
thermal injury to the brain tissue.
To position the impactor device, the impactor tip was centered in
the craniectomy site perpendicular to the exposed surface of the
brain at an angle of approximately 45 degrees from the vertical.
Then the tip was lowered until it just touched the dural surface. The
impactor rod was then retracted, and the tip advanced an additional
distance to produce a brain deformation of 2.5 mm at the time of the
impact. To induce a mild injury, the controlled cortical impact
device was adjusted to 35 psi, giving an impact velocity of 3 m/sec.
With the help of a heating lamp aimed at the head of the rat, the
brain temperature was kept between 36 and 37C. Body tempera-
ture was continuously monitored and maintained between 36 and
37C with a heating pad controlled by a rectal probe.
After the cortical injury the skull defect was closed using an
artificial bone flap made of dental acrylic to avoid extrusion of brain
tissue. The incision was then closed using 5-0 Vicryl sutures.
Postoperative management and assessment
Anesthesia was discontinued to allow the rats to recover. Escape,
righting, head support, corneal, pinna, paw, and tail reflexes were
assessed and recorded every minute for a maximum of 30 min until
the animal was awake and breathing spontaneously. The animals
were then returned to their cages and allowed free access to food
and water. The animals were given buprenorphine 0.05 mg/kg
subcutaneously daily for analgesia, and fluoroquinolone 0.05 mL/
kg subcutaneously daily to prevent postoperative infections for 3
days post-injury.
The weight of each rat was recorded on the day before surgery,
on the day of surgery, on days 1–5 post-surgery, and on days 17–21
post-surgery, using a manual scale. On days 1–5 post-injury, the
animals performed beam-walking and beam-balancing tasks. On
days 17–21 post-injury, the animals were tested on the Morris
water maze task. Following the last behavioral assessment, the
animals were euthanized and the brains removed for histological
examination.
Behavioral testing
Beam-walking task. Each rat was pre-trained 2 days before
surgery to walk down a beam that was 1 m long, 2.5 cm wide, and
1 m above the ground, into a darkened goal box to escape white
noise of 90 db. At the beginning of each training and test trial, the
rat sat in the goal box for 30 sec. During training trials, the animal
was placed at successively longer distances from the goal box
(fifths of the way) until it learned to walk down the entire beam.
Any distance from which the rat did not walk down the beam into
the goal box was repeated until it did. The rat was given a 30-sec
rest period in the goal box between trials. After it had traversed the
beam in 5 sec or less on three successive trials, four plastic pegs
(7.5 cm high) were placed in holes in the beam at approximately 20-
cm intervals alternating from side to side, 5 mm in from the edge of
the beam. The rat was then trained to another criterion of three
consecutive trials completed in 10 sec or less. If both of these cri-
teria were not met by 30 trials, the rat was disqualified. The final
criterion for inclusion in the study was beam walking times on the
day of surgery with the pegs present that were 5 sec or less on three
consecutive trials within 15 trials. Beam walking with the pegs
present was assessed on days 1–5 post-surgery.
Beam-balancing task. Each rat was placed lengthwise along
the center of a beam 1.5 cm wide, 1 m long, and 1 m above the
ground. The rat was required to balance on the beam for 60 sec for
three trials on the day of surgery, and was attempted again on days
1–5 post-surgery. The rat was taken off the beam and placed in the
goal box for 30 sec between trials.
Morris water maze test. The Morris water maze consisted of
a 5-foot-diameter galvanized steel pool that contained a 10 · 10-cm
766 ROBERTSON ET AL.
acrylic glass platform 26 cm high and hidden 2 cm below the wa-
ter’s surface. Four sequences that corresponded to both the position
of the platform (1, 2, 3, and 4), and the starting position (north,
south, east, and west quadrants), were developed using a Latin
square. An equal number of rats from each treatment group was
randomly assigned to each trial sequence. Each rat in each group
was given a specific sequence to follow throughout the water maze
trials. The maze was filled with water until it was 2 cm above the
acrylic glass platform. For each trial, the rat was placed in the water
facing the wall in the indicated position. If the rat did not find the
platform within 120 sec on any trial, it was placed on the platform
for 30 sec. If the rat found the platform within 120 sec, it was al-
lowed to remain on the platform for 30 sec. Four trials were per-
formed each day with a 4-min rest period between trials; the rat was
kept warm with a heating lamp between trials. The rat was tracked
in the water maze with a video tracking system. Pre-injury per-
formance was not tested. Instead, maze performance was assessed
on each of days 17–21 post-injury. A probe trial followed the fourth
trial on day 21, in which the platform was removed from the
quadrant and the time spent by the animal in the platform quadrant
was determined. Finally, a visible platform was placed in the
quadrant, and the time taken to find the platform was determined.
Histopathological assessment
On day 21, all animals were deeply anesthetized with 5% iso-
flurane in 100% oxygen and perfused transcardially with normal
saline solution followed by phosphate-buffered 4% paraformalde-
hyde. The entire brain was removed and fixed in 4% paraformal-
dehyde for 24 h, and then transferred to a 30% sucrose solution.
Following sucrose infiltration and immediately prior to subsequent
processing, an 18-gauge needle was inserted ventrally on the left
side of the brain from a rostral to caudal position. The brains were
frozen and sectioned in the coronal plane on a cryostat at a thick-
ness of 30 lm. The sections were sequentially placed in 48-well
plates in a Tris-buffered/polyethylene glycol solution to maintain
tissue integrity when stored at - 20C. Every ninth section was
collected and immediately mounted, in sequential order, onto
gelatin-coated slides and dried on a slide warmer.
The mounted sections were stained with hematoxylin and eosin
(H&E), dehydrated, and cover-slipped. The slides were then
scanned on an Epson Expression 1680 scanner driven by Adobe
Photoshop CS3 at a resolution of 1200 dpi. Lesion volumes were
determined using ImageJ software. Briefly, after establishing scale,
the lesion cavity was outlined and filled, generating the lesion area
per section. The lesion volume per animal was subsequently de-
termined as the sum of the area measurement of each section · the
thickness of the section (30 lm) · the sampling interval.
Quantification of CA1 and CA3 neurons. Neuronal counts
were performed on brain sections immunolabeled with a mono-
clonal antibody raised against the pan-neuronal marker NeuN
(Millipore, Billerica, MA). Briefly, sections were pre-incubated in
PBS containing 0.06% hydrogen peroxide to quench endogenous
peroxidase activity. The sections were then blocked in PBS con-
taining Triton-X100 (Sigma-Aldrich, St. Louis, MO) with 5% horse
serum for 1 h. The sections were then incubated in anti-NeuN an-
tibody (mouse monoclonal; Millipore) overnight at 4C at a con-
centration of 0.75 lg/mL. The sections were then incubated in
horse anti-mouse biotinylated secondary antibody, followed by
avidin-biotin-complex (ABC Elite Kit; Vector Laboratories, Bur-
lingame, CA). NeuN immunoreactivity was subsequently visual-
ized using diaminobenzidine (DAB) as a substrate, with nickel
chloride (8%) to enhance, and hydrogen peroxidase as a catalyst.
The sections were rinsed, mounted, dried, and dehydrated through
increasing concentrations of ethanol. The slides were then cover-
slipped using a non-aqueous mounting medium. Counts of NeuN-
immunoreactive (-IR) neurons were performed in the ipsilateral
hippocampal CA1 and CA3 regions as follows. Six sections per
brain were examined in the coronal plane in a rostral-to-caudal
direction. The range of sections was standardized by comparing
H&E-labeled sections with the images in the rat brain atlas.26 The
rostro-caudal series of NeuN-immunolabeled sections began at the
following approximate coordinates: interaural 6.44 mm, bregma
- 2.56 mm to interaural 4.84 mm, bregma - 4.16 mm. Images were
captured using an Olympus BX61 microscope attached to a SPOT-
RT digital camera under brightfield conditions using a 40 · air
objective, focusing on the CA1 and CA3 regions of the ipsilateral
hippocampus. The captured images were then processed/quantified
using Nikon NIS Elements image analysis software. Individual
neurons within the CA1 and CA3 regions were autodetected in
images thresholded to permit distinct resolution of NeuN-positive
cell bodies. Cells were counted within an image field of
382.35 · 382.35 lm and stored. Data consisted of the cell count
means of the six NeuN-immunolabeled sections.
CD68 visualization and quantification. Cellular immune
response was chosen as an indication of overall inflamma-
tion following mTBI. CD68-immunolabeling was performed on a
standardized rostro-caudal range of tissue sections determined
using the rat brain atlas.26 The rostral range of sections be-
gan at the region indicated at interaural position 5.86 mm, breg-
ma - 3.14 mm, and included every eighth section, for a total of
four sections assayed per animal. The sections were incubated in
primary antibody (CD68 1 lg/mL) overnight at 4C. CD68 was
visualized following subsequent incubation in goat anti-mouse
secondary antibody conjugated to Alexa-Fluor 488 (Invitrogen,
Valencia, CA) for a period of 3 h. The sections were rinsed and
mounted onto glass slides, allowed to dry, then cover-slipped
using Fluoromount-G (Fisher Scientific, Pittsburgh, PA), an
aqueous mounting medium. The sections were imaged on the
same imaging platform described above, using widefield fluo-
rescence parameters at 10 · magnification. CD68-positive cel-
lular profiles were automatically counted with Image Pro +
software (version 7.01; Media Cybernetics, Rockville, MD), us-
ing a user-generated area of interest of 1.48 · 0.97 mm applied to
the ipsilateral hippocampus.
Statistical analysis
Summary data in text, tables, and figures are expressed as
mean – standard error. Data were analyzed with IBM SPSS Sta-
tistics Version 19. Histology parameters were compared using a
two-factor between-groups analysis of variance (ANOVA), with
drug treatment (pHBSP versus control), and time of administration
(early versus delayed), as the factors. The behavioral data over time
were analyzed using a four-factor mixed ANOVA design, involv-
ing between-group effects of drug treatment and time of adminis-
tration, and repeated-measures on day post-injury and trial within
each day, was conducted. Effect size was evaluated with a partial
g2, which is appropriate for ANOVAs having more than one fac-
tor.27,28 Interpretation of partial g2 is usually that 0.04 represents
small, 0.25 medium, and 0.64 large effect size.
Results
Characteristics of the mild TBI model
Contusion volume and neuronal loss in the hippocampus was
minimal with this mild cortical impact injury (Fig. 1). The median
contusion volume from the impact was 0.3 mm3 (interquartile range
0.07–1.3 mm3). The average neuron counts in the CA1 and CA3
regions of the hippocampus were 98 – 3 and 69 – 1, respectively.
Changes in the behavioral characteristics (Fig. 2) were likewise
slight. The average time to recovery of the righting reflex was
slightly increased, from 5.5 – 1.1 min with the mTBI compared to
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4.8 – 0.8 min in sham-injured animals. Poorer performance on the
Morris water maze task was the most consistent abnormality seen
with mTBI (Fig. 2, left). The average time to find the platform was
26.3 – 1.3 sec in the mTBI animals, compared to 18.8 – 1.6 sec in
the sham-injured animals. Beam-balance performance was mildly
impaired on the first post-injury day compared to sham-injured
animals (Fig. 2, center). Beam-walking performance was similar to
that of sham-injured animals (Fig. 2, right).
Effects of pHBSP in the mild TBI model
Recovery of reflexes. As a measure of initial injury severity
(prior to drug treatment), recovery of reflexes was recorded after
the injury.29–31 The recovery time in minutes for escape, head
support, righting, corneal, pinna, paw, and tail reflexes, were ana-
lyzed separately for each reflex, and for a measure combining all
reflexes using two-factor between-groups ANOVA having treat-
ment type and time of administration as the factors. No significant
differences were seen among the treatment groups for any of the
reflexes or for an average reflex measure (Table 1), suggesting that
the injury severity was similar in all groups.
Weight. Weight was recorded at baseline and daily and on
days 1–5 and on days 17–21, as a measure of the general health of
the animals post-injury. In all groups there was a small drop in
weight on day 1 post-injury, with recovery and a gradual increase in
weight thereafter (Table 2). Weight was analyzed separately for
baseline prior to surgery, for days 1–5 post-injury, and for days 17–
21 post-injury. Baseline weight was analyzed by a two-factor
ANOVA with treatment and time of administration as the between-
groups factors. No differences in baseline weight were observed
among the treatment groups, indicating that the groups were similar
in weight before surgery. Three-factor mixed ANOVAs with
treatment and time as the between-groups factors, and days 1–5 or
days 17–21 as the repeated-measures factors, were performed. The
main effects of drug treatment and time of administration, as well as
the drug · time interaction, were not significantly different for ei-
ther days 1–5 or days 17–21.
Effect of pHBSP on behavioral outcome measures
Beam-walking and beam-balance tests. Motor strength
and coordination were tested prior to injury and daily (3 trials/day)
on post-injury days 1–5 using the beam-balance and beam-walking
tests. For the beam-walking test, the length of time required to cross
a narrow beam was recorded for each trial, with a shorter time
representing better performance. For trials in which the rat fell off
or could not complete the task within 30 sec, a value of 31 sec was
used in the analysis. For the beam-balance test, the length of time
that the animals could balance on a narrow beam was recorded for
each trial, with a longer time indicating better performance. The
details of the statistical analysis are summarized in Table 3.
Baseline beam-walking and beam-balance performance were
tested prior to the surgery to produce the impact injury. To analyze
the pre-injury beam walking data, a three-factor mixed ANOVA
with the between-group effects of drug treatment (pHBSP or con-
trol), time of administration (early or late), and repeated measures
on trial (1–3). There were no significant differences in baseline
beam-walking performance by drug treatment or time of adminis-
tration, indicating that the groups had similar performance on these
motor tasks prior to the injury. For the beam-balance task, all an-
imals were able to balance for the full 60 sec prior to injury.
Beam-walking and beam-balance performance post-injury were
analyzed with a mixed four-factor ANOVA design involving the
between-group effects of drug treatment (pHBSP or control), time
of administration (early or late), repeated measures on day (1–5)
post-injury, and trial (1–3) within each day. Beam-walking time
FIG. 1. Typical appearance of the mild cortical impact injury.
The images are taken from a coronal slice of the brain at the
coordinates 5.86 mm from the interaural line and - 3.14 mm from
the bregma.26 No overt tissue damage (cavitation or cell loss) was
observed grossly in either the cortex or underlying hippocampus
under low (A; scale bar = 400 lm) or high magnification (B and
C; scale bar = 200 lm).
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improved significantly over time in all animals, from 5.4 – 0.6 sec
on day 1, to 2.4 – 0.1 sec on day 5. And on each day, beam walking
improved with each subsequent trial. This improvement with re-
peated trials was greatest on day 1. Beam balance also improved
significantly over time, from 42.5 – 2.2 sec on day 1, to
57.8 – 0.9 sec on day 5. There were no significant effects of drug
treatment or time of administration, and the drug · time of ad-
ministration interaction was not significant for either the beam-
walking or beam-balance testing.
Morris water maze test. Spatial learning was tested daily (4
trials/day) using the Morris water maze on post-injury days 17–21.
For trials for which the rat successfully found the platform, the length
of time required was used in the analysis. For trials for which the rat
was not able to find the platform within 120 sec, a value of 121 sec
was assigned for the analysis. The path length traveled to find the
platform and the swim speed were also recorded for each trial. To
analyze these variables, a four-factor mixed ANOVA design in-
volving between-group effects of drug treatment (pHBSP or control),
time of administration (early or late), repeated measures on day (17–
21) post-injury, and trial (1–4) within each day was conducted. The
results of the statistical analyses are summarized in Table 3.
For all rats, the length of time required to find the platform
decreased progressively over time, from 55.5 – 2.3 sec on day 17, to
11.6 – 0.8 sec on day 21 ( p < 0.001, partial g2 = 0.75), and de-
creased on each day with subsequent trials. This decrease with
repeated trials was largest on the first day of testing (day 17 post-
injury), and decreased progressively over the 5 days of testing.
Rats that received pHBSP required a significantly shorter time to
find the platform, 22.4 – 1.2 sec, compared to 26.3 – 1.2 sec in rats
that received control treatment ( p = 0.022, partial g2 = 0.08). The
rats that received pHBSP also traveled a significantly shorter dis-
tance to get to the platform, 5.0 – 0.3 meters, compared to 6.1 – 0.3
meters in rats that received control treatment ( p = 0.019, partial
g2 = 0.09). There was no significant interaction between the drug
treatment and the time of administration for either time to find the
platform or for distance traveled to get to the platform, suggesting
that the improvement in spatial learning with pHBSP was similar
when given early after injury and when delayed until 24 h post-injury.
The average time to find the platform over all 5 days of testing is
shown in Figure 3 (lef). Plots of the average time to find the platform
for each day of testing are shown in Figure 4 (animals treated early on
the left, animals treated at 24 h on the right). The average distance
traveled to find the platform over all 5 days of testing is shown in
Figure 3 (right). For both the early and the late treatment times, the
animals treated with pHBSP required a shorter time to find the
platform compared to the rats that received control treatment.
There was also a significant main effect of administration time
( p = 0.014, partial g2 = 0.10), with the animals that were treated
early post-injury (both pHBSP- and control-treated animals) re-
quiring longer to find the platform than animals having treatment
that was delayed 24 h. This effect can be seen in Figure 4, where the
average time to find the platform for both early treatment groups
(pHBSP and control) was longer than the times for both late
treatment groups on the first day of testing. Since this difference
was not limited to a specific treatment (pHBSP or control), it was
not clear what aspect of administering the drug early post-injury
resulted in this finding.
Swim speed in meters per second decreased significantly over
time ( p = 0.001, partial g2 = 0.75). There was a significant drug ·
time of administration interaction ( p = 0.027, partial g2 = 0.08),
with the rats treated with pHBSP early having a slower swim speed
than the control rats treated early, while the rats treated with pHBSP
at 24 h post-injury had a faster swim speed than control rats treated
at 24 h post-injury. Swim speed was not related to the group dif-
ferences in time to find the platform.
The time required to find the platform on post-injury day 21
during the probe trial and the visible platform trial were analyzed
FIG. 2. Behavioral characteristics of the mild traumatic brain injury (TBI) model, showing transient beam balancing deficits and mild
impairment on the Morris water maze test compared to sham-injured animals.
Table 1. Recovery of Reflexes after Injury for the Treatment Groups
Early treatment (min) Delayed treatment (min)
Main effects
p values (partial g2)
Recovery of reflex
(minutes after injury) pHBSP Control pHBSP Control Drug Time of administration
Escape reflex 7.4 – 0.5 6.9 – 0.4 6.7 – 0.4 6.9 – 0.2 0.478 (0.01) 0.387 (0.01)
Head support reflex 6.6 – 0.4 6.2 – 0.4 6.1 – 0.3 6.2 – 0.3 0.484 (0.01) 0.484 (0.01)
Righting reflex 6.0 – 0.4 5.6 – 0.4 5.4 – 0.3 5.6 – 0.2 0.487 (0.01) 0.372 (0.01)
Corneal reflex 4.8 – 0.3 4.4 – 0.3 4.3 – 0.2 4.5 – 0.2 0.442 (0.01) 0.442 (0.01)
Pinna reflex 4.6 – 0.3 4.1 – 0.3 3.9 – 0.2 4.2 – 0.2 0.501 (0.01) 0.347 (0.02)
Paw reflex 3.5 – 0.3 3.0 – 0.3 2.6 – 0.2 3.1 – 0.2 0.813 (0.01) 0.160 (0.03)
Tail reflex 4.0 – 0.3 3.6 – 0.2 3.5 – 0.2 3.7 – 0.2 0.477 (0.01) 0.320 (0.03)
pHBSP, pyroglutamate helix B surface peptide.
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using a two-factor ANOVA, with between-groups factors of drug
treatment (pHBSP or control), and time of administration (early
or late). There was no significant difference in performance dur-
ing these tasks for drug treatment, time of administration, or an
interaction.
Effect of pHBSP on histological outcome measures
As described under the characteristics of the mTBI model, con-
tusion volume and neuronal loss in this mild injury was small in the
majority of animals. Only 11 animals (17%, 2 or 3 animals per
treatment group) had a contusion volume greater than 2 mm3. Con-
tusion volume was not significantly different among the treatment
groups. Likewise neuronal loss in the hippocampus was minimal, and
there were no significant differences among treatment groups.
As a measure of the cellular inflammatory response to injury
(Fig. 5), cells of monocyte/macrophage origin were labeled and
counted using an antibody against CD68-IR cells in the hippo-
campus ipsilateral to the lesion site. Despite the minor nature of the
contusion, there were numerous CD68-labeled cells in the majority
of animals. The number of CD68-labeled cells was significantly
less in the animals treated with pHBSP, 116 – 24 compared to
188 – 24, in the control animals (drug effect p = 0.043, partial
g2 = 0.07). As shown in the graph in Figure 5, the reduction in
inflammation was similar regardless of the time of the start of
treatment (drug · time of administration interaction p = 0.744).
Table 2. Weight of the Animals Over Time in the Treatment Groups
Early treatment (g) Delayed treatment (g) Main effects
p values (partial g2)
pHBSP Control pHBSP Control Drug Time of administration
Baseline 366 – 8 369 – 8 360 – 7 371 – 8 0.416 (0.01) 0.840 (0.01)
Day 1 361 – 8 361 – 9 353 – 7 368 – 8 0.389 (0.01) 0.913 (0.00)
Day 2 363 – 8 364 – 8 354 – 7 369 – 8
Day 3 366 – 7 365 – 8 356 – 7 371 – 8
Day 4 367 – 7 367 – 9 358 – 7 373 – 8
Day 5 368 – 7 369 – 9 361 – 6 376 – 8
Day 17 413 – 7 413 – 11 408 – 6 425 – 14 0.211 (0.03) 0.573 (0.01)
Day 18 415 – 7 414 – 12 410 – 6 427 – 14
Day 19 416 – 7 415 – 12 411 – 6 429 – 14
Day 20 417 – 7 416 – 12 414 – 7 432 – 14
Day 21 419 – 7 418 – 12 414 – 6 433 – 14
pHBSP, pyroglutamate helix B surface peptide.
Table 3. Details of the Statistical Analysis of the Outcome Measures
p Values (partial g2) for main effects
















Contusion volume 0.817 (0.06) 0.252 (0.02) 0.787 (0.06)
CA1 neuron count 0.312 (0.02) 0.768 (0.00) 0.590 (0.01)
CA3 neuron count 0.917 (0.00) 0.558 (0.01) 0.220 (0.03)
CD68-labeled cell count 0.040 (0.07) 0.723 (0.00) 0.767 (0.00)
Morris water maze (four-factor mixed ANOVA)
Time to find platform 0.022 (0.08) 0.014 (0.10) 0.000 (0.75) 0.000 (0.34) 0.901 (0.00) 0.000 (0.16)
% Time spent in platform quadrant 0.825 (0.00) 0.148 (0.03) 0.000 (0.19) 0.000 (0.19) 0.860 (0.00) 0.000 (0.25)
Distance traveled to find platform 0.019 (0.09) 0.029 (0.08) 0.000 (0.74) 0.000 (0.34) 0.599 (0.01) 0.000 (0.16)
Swim speed 0.448 (0.01) 0.534 (0.01) 0.000 (0.11) 0.028 (0.05) 0.027 (0.08) 0.000 (0.17)
Probe trial: time spent in platform
quadrant
0.416 (0.01) 0.954 (0.00) 0.914 (0.00)
Visible platform: time to
find platform
0.263 (0.02) 0.996 (0.00) 0.177 (0.03)
Beam walking (three- or four-factor mixed ANOVA)
Pre-injury time to cross beam 0.458 (0.01) 0.895 (0.00) 0.000 (0.13) 0.411 (0.01)
Post-injury time to cross beam 0.658 (0.00) 0.294 (0.02) 0.000 (0.34) 0.000 (0.14) 0.366 (0.01) 0.001 (0.05)
Beam balance (four-factor mixed ANOVA)
Post-injury balance time 0.815 (0.00) 0.911(0.00) 0.000 (0.38) 0.178 (0.028) 0.997 (0.00) 0.012 (0.04)
pHBSP, pyroglutamate helix B surface peptide; ANOVA, analysis of variance.
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Summary of pHBSP effects
In summary, the major significant findings in this mTBI model
are an improvement in Morris water maze performance and a re-
duction in the number of inflammatory cells in the injured cortex
with pHBSP administration.
Discussion
pHBSP has been shown to have cytoprotective activity in
models of stroke, myocardial and renal ischemia-reperfusion, renal
and neuronal cisplatinum toxicity, diabetic neuropathy and reti-
nopathy, sciatic nerve crush injury, status epilepticus, wound
healing, and other models, when administered at doses in the range
of 0.5–10 lg/kg.32–36
In a previous TBI study, pHBSP at a dose of 30 lg/kg every 12 h
for 3 days reduced contusion volume and improved neurobeha-
vioral recovery in a model of mTBI followed by hemorrhagic
shock.25 Contusion volume was decreased by 70%, and neurobe-
havioral improvements were limited to motor tasks. The current
study shows that pHBSP also improves some aspects of neuro-
logical outcome in an uncomplicated mTBI model. In addition,
these improvements were no different when administration was
delayed until 24 h post-injury.
Some aspects of these treatment effects with pHBSP are similar
to those that have been described with EPO, and with the EPO
derivative carbamylated EPO (CEPO) in more severe traumatic
injuries. When EPO or CEPO were given within 6 h of severe TBI,
major reductions in contusion volume and cellular inflammatory
response,21 and improvements in hippocampal neuronal survival
have been observed.14,15,37 Improvements in performance on be-
havioral tasks also occur.37 When treatment is delayed until 24 h
post-injury, contusion volume is not reduced, but preservation of
hippocampal neurons and improvement in performance on the
Morris water maze task have been reported.37,38 These improve-
ments with delayed treatment despite the lack of preservation of
tissue at the impact site have been attributed to enhancement of
recovery through neurogenesis. The lack of effect on contusion
volume and hippocampal neuronal survival with early adminis-
tration of pHBSP in the uncomplicated mTBI model is likely due to
the very minor nature of the cellular loss in this mild TBI model.
Improvements in cognitive function with EPO have also been
noted in patients treated with EPO for anemia,39 in normal volun-
teers who have been given single doses of EPO,40,41 and in
schizophrenic patients treated for 3 months with weekly injections
of EPO.40 Because the current study did not include a drug-treated
and placebo-treated sham-injury group, it cannot be determined if
the improvements on the Morris water maze task are due to neu-
roprotection/neurorestoration following mTBI, or to this enhance-
ment of cognitive function that has been observed with EPO-like
agents in other conditions.
The minor deficits due to the nature of the mild injury could be
viewed as a limitation of the present study. The injury resulted in a
very small contusion and only modest behavioral deficits compared
to sham-injured animals. Therefore the improvements seen with
any drug treatment would be necessarily small in this model. Per-
formance on the motor tasks in the mTBI model was only
FIG. 4. Average time to find the platform by day after injury was slightly shorter in the animals that received pHBSP compared to
those that received control treatment, both with early treatment (left) and with treatment at 24 h post-injury (right). These differences
were greatest on the first 2 days of testing (pHBSP, pyroglutamate helix B surface peptide).
FIG. 3. The average time to find the platform was significantly shorter (left, p = 0.022), and the distance traveled to find the platform
was shorter (right, p = 0.019), in the animals treated with pHBSP compared to the control animals (pHBSP, pyroglutamate helix B
surface peptide).
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transiently impaired (beam-balance test), or not impaired at all
(beam-walking test), compared to sham-injured animals. No con-
sistent improvements were seen in motor performance with
pHBSP. The results in the Morris water maze showed a small but
significant improvement in the time required to find the platform
with pHBSP.
While this characteristic of the mTBI model could be considered
a limitation of the study, this is also the nature of mTBI in humans.
The major consequences of mTBI are cognitive problems and post-
concussive symptoms. Motor symptoms are uncommon. The post-
concussive symptoms that occur with mTBI are difficult to model
in rodents, but cognitive tests are widely used in rodent studies. The
Morris water maze is one of the more common rodent tests of
cognition. It tests acquisition of spatial navigation, and is sensitive
to hippocampal injury. In humans, wayfinding is commonly im-
paired after TBI, and spatial navigation has been tested and been
found to be impaired using a virtual reality simulation of the Morris
water maze.42 Therefore the findings of improved Morris water
maze performance should be pertinent to mTBI patients. Other tests
in future preclinical studies involving the mTBI model might in-
clude tasks of working memory and conflict active avoidance
tasks.43,44
Another limitation of the study is the confounding finding of the
time of administration. This finding did not seem to be related to the
treatment, because both the pHBSP-treated and the control-treated
animals had better performance in the Morris water maze with
delayed treatment, compared to early treatment. It is possible that
this was due to an imbalance in the randomization, with more
severely injured animals being randomized to the two early treat-
ment groups. However, the time to recovery of the righting reflex,
which was used as a measure of the pre-treatment injury severity,
was similar in all treatment groups. The only difference in the way
that the early- and delayed-treatment animals were managed was in
receiving the first dose of the drug at 1 h post-injury or at 24 h post-
injury, respectively. Stress can alter physiological parameters in
rodents, and could potentially alter the outcome from an mTBI
injury. For example, an IP injection of saline can result in an in-
creased glucocorticoid response to a second saline injection.45
Restraint stress can even alter aspects of brain metabolism, such as
amyloid-beta and brain-derived neurotrophic factor production.46
A stronger study design that might have allowed better comparison
of the early and late treatments would have been to give the delayed
treatment groups placebo injections on the day of injury.
The neuroprotective/neurorestorative mechanism of action for
pHBSP is thought to be similar to that of EPO, with actions that
include anti-inflammatory effects and inhibition of apoptosis.
Following experimental TBI, administration of EPO attenuated the
injury-induced increase in interleukin-1b and tumor necrosis fac-
tor-a in the brain.47,48 Interleukin-6 levels and reduced numbers of
activated glial cells have also been reported to be lower following
EPO administration.21,49 The finding of a decrease in CD68-labeled
cells is consistent with the reports for EPO,21 and suggests that
inhibition of the inflammatory response to mTBI may play a role in
the improved outcome seen with pHBSP in our mTBI model. Cy-
toprotective activities of pHBSP in other models have also included
anti-inflammatory activities. In a hemorrhagic shock model,
pHBSP significantly reduced the inflammatory response and sub-
sequent injury to the lungs.50 The mechanism was thought to be due
to activation of Akt, which enhances tissue survival by inhibiting
GSK-3b, and it also inhibits the inflammatory response to hemor-
rhage by reducing the injury-induced activation of NF-jB. In a
myocardial ischemia model induced by permanent ligation of a
coronary artery, pHBSP decreased the infarct size when given in a
dose of 1–60 lg/kg at 5 min after the ligation, but no change was
seen when it was given 24 h after the ligation. pHBSP reduced the
number of inflammatory cells (neutrophils and macrophages) by
34% in the area of myocardium at risk.32
Conclusions
The studies suggest that pHBSP may be a useful drug for mTBI.
The findings of an improvement in spatial navigation acquisition
are relevant to the cognitive impairments seen with TBI. Treatment
with pHBSP can be delayed as long as 24 h post-injury, which is
important with mTBI. Unlike more severe injuries, for which pa-
tients are brought immediately to the hospital after the accident,
mTBI patients may not be as rapidly evaluated. Finally, since
pHBSP does not stimulate erythropoiesis, it may be safer than EPO
in a disorder like mTBI, for which the hemoglobin concentration is
usually normal.
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